{"id":"folfrinox","safety":{"commonSideEffects":[{"rate":"70-80","effect":"Neutropenia"},{"rate":"50-70","effect":"Anemia"},{"rate":"40-50","effect":"Thrombocytopenia"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"50-70","effect":"Diarrhea"},{"rate":"40-60","effect":"Peripheral neuropathy"},{"rate":"60-80","effect":"Fatigue"},{"rate":"30-50","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFRINOX combines 5-fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and irinotecan. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; oxaliplatin is a platinum agent that creates DNA crosslinks; and irinotecan inhibits topoisomerase I. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"FOLFRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:03.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Metastatic colorectal cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT05669092","phase":"PHASE3","title":"A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-11-01","conditions":"Toripalimab, Radiation","enrollment":174},{"nctId":"NCT05566743","phase":"PHASE2","title":"A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas","status":"UNKNOWN","sponsor":"Menoufia University","startDate":"2022-09-11","conditions":"Cancer of Pancreas","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Irinotecan,Oxaliplatin and 5-FU"],"phase":"phase_3","status":"active","brandName":"FOLFRINOX","genericName":"FOLFRINOX","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells. Used for Metastatic pancreatic cancer, Metastatic colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}